Prescribing information available here
Adverse event reporting information can be found at the bottom of this page
Easyhaler® is a fully carbon neutral product range, produced in Finland, enabling climate-friendly and environmentally conscious decision-making in asthma and COPD care, for physicians and patients alike.1
Bufomix Easyhaler Contraindications and Undesirable effects
Contraindications: Hypersensitivity to the active substances or lactose monohydrate (which contains small amounts of milk protein).
Undesirable effects:
Common (≥1/100 to < 1/10): Candida infections in the oropharynx, pneumonia (in COPD patients) headache, tremor, palpitations, mild irritation in the throat, coughing, dysphonia including hoarseness.
See SmPC for full list of adverse reactions
Date of preparation: October 2024 / EASYH-2727(1)
Reference
- Carbon life cycle assessment report for Orion Corporation, Orion Pharma. Executive summary. Carbon Footprint Ltd 2021. Available at: Orion.fi/en
DATE OF PREPARATION: MAY 2023/EASYH-688(10)
FULL PRESCRIBING INFORMATION AVAILABLE HERE
For more information about Orion and Sustainability click here
| Adverse effects should be reported. You can report side effects directly via the Health Products Regulatory Authority (HPRA) website: www.hpra.ie or by email on medsafety@hpra.ie. Adverse effects should also be reported to Orion Pharma via ie.medicalinformation@orionpharma.com |
